Interleukin 6 receptor inhibitors in the treatment of rheumatoid arthritis during the COVID-19 pandemic, Moscow experience

Interleukin 6 receptor inhibitors in the treatment of rheumatoid arthritis during the COVID-19 pandemic, Moscow experience

Objective: to confirm the efficacy and safety of levilimab in patients with rheumatoid arthritis (RA) switched from other interleukin 6 receptor inhibitors (iIL6R) for non-medical reasons.Patients and methods. A retrospective analysis of data from the register of patients with RA who during the COVI...

Full description

Bibliographic Details
Main Authors:	A. I. Zagrebneva, E. N. Simonova, T. V. Mezenova, N. B. Burmistrova, Yu. A. Gavrikova, E. O. Morozova, Zh. M. Kodzeva, K. S. Sapogina
Format:	Article
Language:	Russian
Published:	IMA-PRESS LLC 2022-12-01
Series:	Современная ревматология
Subjects:	ревматоидный артрит генно-инженерный биологический препарат ингибитор рецептора интерлейкина 6 левилимаб немедицинское переключение
Online Access:	https://mrj.ima-press.net/mrj/article/view/1375

Similar Items

Effectiveness and safety of levilimab in combination with methotrexate in treatment of patients with active rheumatoid arthritis resistant to methotrexate monotherapy (double-blinded randomized placebo controlled phase III clinical study SOLAR)
by: V. I. Mazurov, et al.
Published: (2021-08-01)

PROGNOSTIC FACTORS FOR THE RESPONSE TO TOCILIZUMAB THERAPY IN PATIENTS WITH JUVENILE IDIOPATHIC ARTHRITIS WITHOUT SYSTEMIC MANIFESTATIONS: A COHORT STUDY
by: Ekaterina I. Alexeeva, et al.
Published: (2018-07-01)

Early Predictors of the Response to Adalimumab Therapy in Patients With Juvenile Idiopathic Arthritis Without Systemic Manifestations: A Prospective Cohort Study
by: Ekaterina I. Alexeeva, et al.
Published: (2018-12-01)

Early Prognostic Factors for Remission Achievement at Etanercept Therapy in Patients with Juvenile Idiopatic Arthritis Without Systematic Manifestations: Prospective Cohort Study
by: Ekaterina I. Alexeeva, et al.
Published: (2019-04-01)

Оценка переносимости и безопасности комплексной терапии вторичного остеоартроза у больных ревматоидным артритом с учетом коморбидной патологии
Published: (2016-12-01)

TREATMENT WITH GENETICALLY ENGINEERED BIOLOGICAL AGENTS: EFFICACY AND SAFETY OF CHANGEOVER
by: A. A. Baranov, et al.
Published: (2014-01-01)

Safety of using genetic engineering biological agents in rheumatoid arthritis
by: N V Chichasova, et al.
Published: (2010-03-01)

USE OF THE NEW GENETIC ENGINEERING BIOLOGICAL AGENT TOCILIZUMABIN THE TREATMENT OF RHEUMATOID ARTHRITIS
by: E L Nasonov, et al.
Published: (2010-03-01)

Biological agents for endoprosthetic joint replacement in patients with rheumatoid arthritis
by: Viktoria Nikolaevna Khlaboshina, et al.
Published: (2014-12-01)

Rheumatoid arthritis in real clinical practice: initiation of therapy with biological agents. Results of the «Computer Terminals of Self-Assessment for Patients with Rheumatic Diseases» («TERMINAL-II») project
by: V. N. Amirdzhanova, et al.
Published: (2019-09-01)

A CURRENT VIEW ON THE PROBLEM OF RAPIDLY PROGRESSIVE RHEUMATOID ARTHRITIS
by: Dmitry Evgenyevich Karateyev
Published: (2010-06-01)

POSSIBILITIES FOR PRESERVING THE RESULTS OF TREATMENT IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS AFTER DOSE REDUCTION AND/OR DISCONTINUATION OF BIOLOGICAL AGENTS: A REMARCA STUDY
by: E. L. Luchikhina, et al.
Published: (2016-12-01)

TREATMENT OF PATIENTS WITH RHEUMATOID ARTHRITIS WITH COMBINED PATHOLOGY
by: D. I. Khusainova, et al.
Published: (2020-06-01)

Difficult-to-treat rheumatoid arthritis in the clinical practice of a rheumatological hospital. First look
by: A. V. Gordeev, et al.
Published: (2022-05-01)

Combination therapy with leflunomide and genetic engineering biological agents
by: Nataliya Vladimirovna Chichasova, et al.
Published: (2011-06-01)

Inhibitors of interleukin 17A in the treatment of psoriatic arthritis: what's new?
by: Т. V. Korotaeva
Published: (2021-04-01)

Pharmacoeconomic analysis of using biological agents in the treatment of rheumatoid arthritis
by: I. I. Dyakov, et al.
Published: (2014-09-01)

The prediction and long-term maintenance of low disease activity during therapy with disease modifying anti-inflammatory drugs for rheumatoid arthritis
by: E.L. Luchikhina
Published: (2014-05-01)

An angiotensin-converting enzyme inhibitor in the combination treatment of rheumatoid arthritis
by: E. B. Komarova, et al.
Published: (2017-09-01)

The marked and rapid therapeutic effect of tofacitinib in combination with subcutaneous methotrexate in a rheumatoid arthritis patient with poor prognostic factors who is resistant to standard disease-modifying antirheumatic drugs and biologicals: A clinical case
by: N. V. Demidova, et al.
Published: (2016-03-01)

Experience with tofacitinib in the treatment of resistant rheumatoid arthritis
by: A. R. Babaeva, et al.
Published: (2015-06-01)

The problem of laboratory monitoring in therapy with disease-modifying antirheumatic drugs and biological agents in patients with rheumatoid arthritis
by: Yu. V. Muravyev, et al.
Published: (2018-09-01)

Personalized medicine: Predictors for the efficiency of biological agent therapy for rheumatoid arthritis
by: M. A. Kotovskaya, et al.
Published: (2017-04-01)

Features of the subpopulation composition of dendritic cells in patients with rheumatoid arthritis
by: M. A. Korolev, et al.
Published: (2019-09-01)

The use of an interleukin 1 inhibitor in a patient with atypical course of periodic fever
by: M. S. Eliseev, et al.
Published: (2021-06-01)

Abatacept and cardiovascular risk in rheumatoid arthritis: update
by: T. V. Popkova
Published: (2018-01-01)

Experience with long-term use of certolizumab pegol (Cimzia)
by: Karine Arnoldovna Lytkina, et al.
Published: (2013-10-01)

The tumor necrosis factor-α inhibitor golimumab in the treatment of rheumatoid arthritis
by: Natalia Vladimirovna Chichasova
Published: (2014-12-01)

Rheumatoid arthritis: problems of treatment at the present stage
by: N. V. Chichasova
Published: (2018-12-01)

New etanercept biosimilar — expanding treatment options for immune-mediated inflammatory rheumatic diseases
by: A. E. Karateev, et al.
Published: (2022-12-01)

Possible reasons for the inefficacy of genetically engineered biological agents in rheumatoid arthritis and ways of its prevention
by: Natalia Vladimirovna Chichasova
Published: (2012-06-01)

Predictors of biologic disease modifying antirheumatic drugs withdrawal due to the development of adverse events in patients with rheumatoid arthritis
by: E. N. Koltsova, et al.
Published: (2022-12-01)

Ревматоидный артрит: лечение до достижения цели
by: Editorial Article
Published: (2013-12-01)

Efficiency and safety of leflunomide in rheumatoid arthritis: Results of a Russian observational multicenter of trial
by: R. M. Balabanova, et al.
Published: (2015-06-01)

Rationales for discontinuation of disease-modifying antirheumatic drugs, biologic agents, and tofacitinib in rheumatoid arthritis
by: Yu. V. Muraviev, et al.
Published: (2018-12-01)

RHEUMATIC DISEASES AND TUBERCULOSIS INFECTION IN CHILDREN AND ADULTS
by: G. V. Santalova, et al.
Published: (2019-03-01)

OPTIMIZATION OF PHARMACEUTICAL CARE FOR JUVENILE RHEUMATOID ARTHRITIS AT THE REGIONAL LEVEL
by: A. A. Skripko, et al.
Published: (2018-01-01)

Infliximab in Russian clinical practice
by: G V Lukina, et al.
Published: (2012-09-01)

Treatment strategy for rheumatoid arthritis: hot topics
by: D. E. Karateev
Published: (2015-03-01)

Evaluating the effect of a Russian rituximab biosimilar used to treat patients with rheumatoid arthritis on healthcare budgets
by: R. O. Dreval
Published: (2018-06-01)